BioCentury
ARTICLE | Company News

Icos and Abbott extend inflammation deal

June 22, 2000 7:00 AM UTC

ICOS acquired additional rights to ABT's technology and compounds to LFA-1 antagonists to treat inflammation. The companies formed the collaboration in 1995 under which ICOS had marketing rights in ca...